Clinical Trial Update: The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the effect of Rituximab on stem cell mobilization when used with AMD3100 (plerixafor) and G-CSF in relapsed or refractory Non-Hodgkin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Filgrastim (Neupogen) (filgrastim)
• Plerixafor (Mozobil) (plerixafor)
• Rituximab (rituximab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non-Hodgkin Lymphoma, Hodgkin Disease | Phase 2 | Status: COMPLETED | Results posted: 2010-07-29